drugset / Trial / NCT01794793
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
Timeline
- Start
- 2013-06-10
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pasireotide | Other / unclassified | 0.3 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 0.6 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 0.9 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 10 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 20 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 60 mg | Subcutaneous |
| Background | Cabergoline | Small molecule | 0.5 mg | Oral |
| Background | Cabergoline | Small molecule | 1 mg | Oral |